Hormonal
Overexpression of the mitochondrial deacetylase SIRT3 increases FOXO3a DNA-binding activity and upregulates the expression of antioxidant genes (MnSOD and SCO2), thereby reducing intracellular superoxide levels.
This research identifies a specific biological pathway where the protein SIRT3 interacts with FOXO3a inside the mitochondria to boost the body's antioxidant defenses. While this mechanism is crucial for cellular health and longevity, it is a complex internal process. There is no direct dietary or exercise protocol in this paper that targets this specific interaction; however, maintaining mitochondrial health through balanced nutrition and exercise is the general approach to supporting these natural cellular repair systems.
Overexpression of a wild-type SIRT3 gene increase FOXO3a DNA-binding activity as well as FOXO3a dependent gene expression. Biochemical analysis of HCT116 cells over expressing the deacetylation mutant, as compared to wild-type SIRT3 gene, demonstrated an overall oxidized intracellular environment, as monitored by increase in intracellular superoxide and oxidized glutathione levels.
Why this rating
The study uses in vitro cell line models (HCT116, Cos-7) and stable transfection, lacking in vivo or human clinical data.
Source
<i>SIRT3</i> interacts with the <i>daf-16</i> homolog <i>FOXO3a</i> in the Mitochondria, as well as increases <i>FOXO3a</i> Dependent Gene expression
Kristi Muldoon Jacobs et al. · International Journal of Biological Sciences · 2008
DOI 10.7150/ijbs.4.291
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →